Enterprise League logo
Spero Therapeutics Logo

Spero Therapeutics

Cambridge, United States (US) · Science and Engineering

Do your work at Spero Therapeutics?

Claim this profile to manage your company.

Verified by Enterprise League

Data quality

Complete · Accuracy

Last verified

Apr 2026

Overview

We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant ("MDR”) bacterial infections with high unmet need. Our pipeline consists of three mid to late-stage clinical assets. Tebipenem HBr is in Phase 3 development, with the potential to be the first broad-spectrum oral carbapenem to treat complicated urinary tract infections ("cUTIs”) including acute pyelonephritis, caused by certain microorganisms, in adult patients. SPR206 is a Phase 2 ready IV-administered antibiotic being developed as an innovative option to treat MDR Gram-negative bacterial infections in the hospital setting. SPR720, the development of which was recently suspended, is a Phase 2 investigational oral agent for the first-line treatment of nontuberculous mycobacterial ("NTM”) pulmonary disease, a rare disease. As previously disclosed, following the SPR720 program suspension, we are evaluating other potential paths forward as the remaining data are collected and analyzed.

Most teams do this before shortlisting


Contact Details

info@sperotherapeutics.com

Cambridge, United States (US)

Founded

2013

Employees

20-30

Categories

Keywords

#Antibacterial Therapies

#Novel Therapeutics

#Infectious Disease

Companies teams usually look at after Spero Therapeutics

Comparing a few options usually leads to better decisions






  • Save companies to compare later. Useful when sharing options with your team

This is how your company profile looks to others.